Nexstim Oyj: Nexstim Plc Business and Clinical Update Q1 2021 Q1 2021
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces the key highlights of the Company s business and clinical progress during Q1 2021.
CEO Mikko Karvinen s
pdate
Glad to inform that our operational business has had the best start of the year ever while beginning our first full year of executing our renewed strategy. During the first months of 2021, we have continued to invest in the growth of our diagnostic and therapeutic business with the recruitment of two new sales team members to our US organization. At the same time, we are extremely pleased to see that our existing NBS and NBT System customer base has increased the utilisation rate of our installed base to a record level. High utilization of the systems leads into growing levels of high margin recurring revenue, an important element in our profitable growth strategy.
Press release, Helsinki, 13 January 2021 at 13.00 New Study Presents Impressive Results of Nexstim SmartFocus® nTMS Language Mapping Nexstim Plc announces that a new study published in. | January 14, 2021
Nexstim Oyj: New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping
New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that a new study published in
Cancers in January presents impressive results of nTMS language mapping in a large amount of patients. Using the robustness of Nexstim SmartFocus nTMS data, the authors also introduce a new and more precise classification of what it means to be a language eloquent tumour, challenging the traditional methods that seek to only identify hemispheric dominance for language.
The study Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent Gliomas-A Large Scale Comparative Cohort Study Using a New Classification for Language Eloquence , using Nexstim s NBS System with SmartFocus nTMS, was published by a neurosurgical team at Technical University of Munich (TUM) in Germany.